Mingtao Liu

Dr. Mingtao Liu

National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
MLMingtao Liu
Mingtao Liu
HGHui Gan
Hui Gan
YLYilu Lin
Yilu Lin
RLRunpei Lin
Runpei Lin
MXMingshan Xue
Mingshan Xue
Baoqing SunBaoqing Sun
Baoqing Sun
Background: The credible materials about the burden of asthma in China when compared to other countries in the group of twenty (G20) remain unavailable. Objectives and design: Following the popular analysis strategy used in the Global Burden of Disease Study, the age-, sex-, country-specific prevalence, and disability-adjusted life years (DALYs) of asthma in China were analyzed. Meanwhile, the comparison in trends between China and other countries in the G20 was also evaluated. Results: In 2019, asthma was the 8th leading cause of the DALYs’ burden of 369 diseases in China. From 1990 to 2019, the age-standardized prevalence and DALY rates of asthma in China decreased by 14% and 51%, respectively; further, the decline rate of DALYs was much higher than the global average (−51%: −43%). It is worth noting that the overall population age-standardized DALYs rate of asthma in China was the lowest in the G20 during 2019 (102.81, 95% UI: (72.30,147.42)/100,000). Moreover, the age-standardized asthma prevalence rate peaks in both childhood (178.14, 95% UI: (90.50, 329.01)/100,000) and the elderly (541.80, 95% UI: (397.79, 679.92)/100,000). Moreover, throughout the study, subjects in the 5 to 9 years old interval were a constant focus of our attention. Conclusions: The disease burden of asthma has varied greatly by gender and age over the past 30 years. In contrast to the increasing burden in most other G20 countries, the age-standardized prevalence rate of asthma shows a significant decreasing trend in China, however, the age-standardized DALYs rate shows a fluctuating change, and has even shown a rebound trend in recent years.

17 October 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
MLMingtao Liu
Mingtao Liu
MXMingshan Xue
Mingshan Xue
TZTeng Zhang
Teng Zhang
RLRunpei Lin
Runpei Lin
BGBaojun Guo
Baojun Guo
Baoqing SunBaoqing Sun
Baoqing Sun
Background: Higher detection of interstitial pneumonia with autoimmune features (IPAF), and idiopathic pulmonary fibrosis (IPF), has significant diagnostic and therapeutic implications. Some matrix metalloproteinases (MMPs) have become reliable diagnostic biomarkers in IPAF and IPF in previous studies, yet relevant reliability remains to be recognized.Materials and Methods: In this study, 36 ILDs patients, including 31 IPAF patients (Mean ± SD, 50.20 ± 5.10 years; 16 [51.6%] females) and five IPF patients (Mean ± SD, 61.20 ± 6.73 years; one [20.0%] females) were retrospectively enrolled. Serial serum samples were collected from patients with IPAF and IPF between January 2019 and December 2020. Notably, Serum MMPs levels were measured by U‐PLEX Biomarker Group 1(Human) Multiplex Assays (MSD, USA).Results: A combination of MMPs and combinatorial biomarkers was strongly associated with clinical subjects in this study (AUC, 0.597 for Stability vs. Improvement and 0.756 for Stability vs. Exacerbation). Importantly, the AUC of MMP‐12 reaches 0.730 (p < 0.05, Stability AUC vs. Improvement AUC) while MMP‐13 reaches 0.741 (p < 0.05, Stability AUC vs. Exacerbation AUC) showed better performance than other MMPs in two comparisons.Conclusions: Clinical risk factors and MMPs are strongly associated with either stratification of the disease of progression of IPAF or in two IPAF and IPF independent cohorts. To our knowledge, this is the first to illustrate that MMP‐12 and MMP‐13 may be expected to become typical promising biomarkers in Improvement – IPAF and Exacerbation – IPAF, respectively.

15 June 2023 in Reviews in Medical Virology
Verified
Journal Article
Closed access
MLMingtao Liu
Mingtao Liu
ZLZhiman Liang
Zhiman Liang
ZCZhangkai J. Cheng
Zhangkai J. Cheng
LLLi Liu
Li Liu
QLQiwen Liu
Qiwen Liu
BSBaoqing Sun
Baoqing Sun

29 May 2023 in Precision Medical Sciences
Verified
Journal Article
Open access
MLMingtao Liu
Mingtao Liu
ZCZhangkai Cheng
Zhangkai Cheng
MXMingshan Xue
Mingshan Xue
RLRunpei Lin
Runpei Lin
TZTeng Zhang
Teng Zhang
Baoqing SunBaoqing Sun
Baoqing Sun

1 September 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MLMingtao Liu
Mingtao Liu
ZCZhangkai Cheng
Zhangkai Cheng
JCJiaxi Chen
Jiaxi Chen
HLHaiyang Li
Haiyang Li
MXMingshan Xue
Mingshan Xue
Baoqing SunBaoqing Sun
Baoqing Sun
Background: While serum periostin and Krebs von den Lungen-6 (KL-6) have been acknowledged as independent markers in idiopathic pulmonary fibrosis (IPF) diagnosis, the clinical combinatory potential of these biomarkers combined with high-resolution computed tomography (HRCT) has yet to be fully explored. Methods: This retrospective study involved 78 participants, comprising 51 UIP-IPF patients and 27 healthy controls. All subjects underwent clinical and laboratory examinations, particularly the detection of periostin and KL-6 using ELISA with innovative HRCT fibrosis score evaluations at admission and discharge during hospitalization in UIP-IPF patients. Results: In our cohort of patients with IPF, predominantly male, over an average follow-up period of 195.27 days. Serum levels of periostin and KL-6 were significantly elevated in IPF patients compared to healthy controls (*p < 0.05). Post-treatment, KL-6 levels decreased significantly, while periostin levels increased. Notably, periostin exhibited superior prognostic accuracy over KL-6, with a higher AUC of 0.875 than 0.639 in ROC analysis. An increase in periostin levels correlated with disease progression, as evidenced by worsened HRCT fibrotic scores and decreased survival probability. These findings underscore periostin’s potential as a reliable biomarker for assessing IPF severity and therapeutic response. Conclusion: Our findings underscore the preeminence of serum periostin over KL-6 in UIP-IPF diagnosis, particularly when conjoined with HRCT fibrosis score.

12 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TZTeng Zhang
Teng Zhang
YZYifeng Zeng
Yifeng Zeng
RLRunpei Lin
Runpei Lin
MXMingshan Xue
Mingshan Xue
MLMingtao Liu
Mingtao Liu
Baoqing SunBaoqing Sun
Baoqing Sun
(1) Background: Biomarker and model development can help physicians adjust the management of patients with community-acquired pneumonia (CAP) by screening for inpatients with a low probability of cure early in their admission; (2) Methods: We conducted a 30-day cohort study of newly admitted adult CAP patients over 20 years of age. Prognosis models to predict the short-term prognosis were developed using random survival forest (RSF) method; (3) Results: A total of 247 adult CAP patients were studied and 208 (84.21%) of them reached clinical stability within 30 days. The soluble form of suppression of tumorigenicity-2 (sST2) was an independent predictor of clinical stability and the addition of sST2 to the prognosis model could improve the performance of the prognosis model. The C-index of the RSF model for predicting clinical stability was 0.8342 (95% CI, 0.8086–0.8598), which is higher than 0.7181 (95% CI, 0.6933–0.7429) of CURB 65 score, 0.8025 (95% CI, 0.7776–8274) of PSI score, and 0.8214 (95% CI, 0.8080–0.8348) of cox regression. In addition, the RSF model was associated with adverse clinical events during hospitalization, ICU admissions, and short-term mortality; (4) Conclusions: The RSF model by incorporating sST2 was more accurate than traditional methods in assessing the short-term prognosis of CAP patients.